Leading the Way in Life Science Technologies

GEN Exclusives

More »

Best of the Web

More »
Nov 01, 2006 (Vol. 26, No. 19)

The Organometallic HyperTextBook Index

URL:www.ilpi.com/organomet/index.html
  • Good coverge of topic
  • Could have broader scope, better figures
Here’s a site I covered back in the early days of this column, and like many of us with our physicians, it is long overdue for a checkup. Having grown considerably in the past few years, The Organometallic HyperTextBook Index retains its basic philosophy of a descriptive name and a focus on organometallic chemistry while expanding its coverage of this important topic. With over 50 topic areas, some of which were frustratingly unlinked, the site takes no prisoners in its efforts. Individual topic descriptions contain figures, even though they may be a bit primitive, and hyperlinks to other articles. I’d like to see at least a few things at the site aimed at nonresearchers to help increase knowledge of the topic. Otherwise, a very useful site for practitioners.
  • Key:
  • Strong Points
  • Weak Points
  • Ratings:
  • Excellent
  • Very Good
  • Good


*The opinions expressed are solely those of the author(s) and should not be construed as reflecting the viewpoints of the publisher, Genetic Engineering & Biotechnology News, Mary Ann Liebert, Inc., the publishing house, or employees and affiliates thereof.

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »